Finanzen von Cyclerion Therapeutics Inc (CYCN)CYCNCyclerion Therapeutics Inc

Korsana Biosciences, Inc. (CYCN) generates its revenue primarily from Human Therapeutics, which accounts for 100.0% of total sales, equivalent to $133.00K. Understanding this concentration is critical for investors evaluating how CYCN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Korsana Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -98.22%, provide a clear picture of how effectively CYCN converts its operational activities into shareholder value.

In the context of the broader market, CYCN competes directly with industry leaders such as LPCN and UPC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, CYCN's gross margin of N/A stands against LPCN's 100.00% and UPC's 36.99%. Such benchmarking helps identify whether Korsana Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown fluctuating revenues, with a notable increase in Q4 2024 to 1,806,000 USD, but has reported consistent net losses, including a loss of 3,177,000 USD in Q1 2026. Gross margins have been high at 100% in previous quarters but dropped to 0% in 2026, indicating potential operational challenges.